B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer? The following represents disclosure ...

A literature review from 2021 found that as many as 12% of people with an EGFR mutation have a type called the exon 20 insertion mutation. If you have EGFR-positive lung cancer, it means your EGFR ...

The CHMP also recommended marketing authorization for the SC formulation of Rybrevant as a monotherapy for treating adult patients with advanced NSCLC with activating EGFR exon 20 insertion ...

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

They respond to targeted therapies called EGFR inhibitors. Less common EGFR mutations, such as the EGFR exon 20 insertion mutation and EGFR exon T790M mutation, don’t usually respond to EGFR ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...

Initiated a cohort to evaluate ORIC-114 monotherapy for the 1L treatment of patients with NSCLC harboring EGFR exon 20 insertion mutations. Announced the completion of the dose escalation portion ...